Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy
Open Access
- 1 July 2020
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 41 (7) , 446-463
Abstract
No abstract availableKeywords
Funding Information
- Vienna Science and Technology Fund (CS15-033)
- Austrian Science Fund (F3506, F3521, P 32017, SFB35, W1232)
- Novo Nordisk Fonden (NNF17OC0028582)
This publication has 134 references indexed in Scilit:
- Nonclassical Pharmacology of the Dopamine Transporter: Atypical Inhibitors, Allosteric Modulators, and Partial SubstratesThe Journal of Pharmacology and Experimental Therapeutics, 2013
- The Mechanistic Basis for Noncompetitive Ibogaine Inhibition of Serotonin and Dopamine TransportersJournal of Biological Chemistry, 2012
- Unifying Concept of Serotonin Transporter-associated CurrentsJournal of Biological Chemistry, 2012
- Mutational Mapping and Modeling of the Binding Site for (S)-Citalopram in the Human Serotonin TransporterJournal of Biological Chemistry, 2010
- The induction of folding cooperativity by ligand binding drives the allosteric response of tetracycline repressorProceedings of the National Academy of Sciences, 2009
- Hidden dynamic allostery in a PDZ domainProceedings of the National Academy of Sciences, 2009
- Rational modulation of conformational fluctuations in adenylate kinase reveals a local unfolding mechanism for allostery and functional adaptation in proteinsProceedings of the National Academy of Sciences, 2009
- Studies of the Biogenic Amine Transporters. 12. Identification of Novel Partial Inhibitors of Amphetamine-Induced Dopamine ReleaseThe Journal of Pharmacology and Experimental Therapeutics, 2008
- The binding sites for cocaine and dopamine in the dopamine transporter overlapNature Neuroscience, 2008
- Dynamically driven protein allosteryNature Structural & Molecular Biology, 2006